HQH
Income statement / Annual
Last year (2024), Tekla Healthcare Investors's total revenue was $10.77 M,
an increase of 4.64% from the previous year.
In 2024, Tekla Healthcare Investors's net income was $184.95 M.
See Tekla Healthcare Investors,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$10.77 M |
$10.29 M |
$8.27 M |
$6.48 M |
$8.93 M |
$7.60 M |
$6.78 M |
$5.62 M |
$4.80 M |
$4.33 M |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$10.77 M
|
$10.29 M
|
$8.27 M
|
$6.48 M
|
$8.93 M
|
$7.60 M
|
$6.78 M
|
$5.62 M
|
$4.80 M
|
$4.33 M
|
| Gross Profit Ratio |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
| Research and Development Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| General & Administrative Expenses |
$10.93 M
|
$11.48 M
|
$11.94 M
|
$12.71 M
|
$10.90 M
|
$10.47 M
|
$10.90 M
|
$10.78 M
|
$11.08 M
|
$12.18 M
|
| Selling & Marketing Expenses |
$56,394.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$10.99 M
|
$11.48 M
|
$11.94 M
|
$12.71 M
|
$10.90 M
|
$10.47 M
|
$10.90 M
|
$10.78 M
|
$11.08 M
|
$12.18 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$10.99 M
|
$11.48 M
|
$11.94 M
|
$12.71 M
|
$10.90 M
|
$10.47 M
|
$10.90 M
|
$10.78 M
|
$11.08 M
|
$12.18 M
|
| Cost And Expenses |
$10.99 M
|
$11.48 M
|
$11.94 M
|
$12.71 M
|
$10.90 M
|
$10.47 M
|
$10.90 M
|
$10.78 M
|
$11.08 M
|
$12.18 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$220,271.00
|
$1.19 M
|
$3.67 M
|
$6.23 M
|
$1.97 M
|
$2.87 M
|
$4.12 M
|
$5.16 M
|
$6.28 M
|
$7.85 M
|
| EBITDA |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-0.02
|
-0.12
|
-0.44
|
-0.96
|
-0.22
|
-0.38
|
-0.61
|
-0.92
|
-1.31
|
-1.81
|
| Total Other Income/Expenses Net |
$185.17 M
|
$57.52 M
|
-$190.56 M
|
$161.41 M
|
$243.18 M
|
-$142.42 M
|
$73.32 M
|
$126.45 M
|
-$49.74 M
|
$104.02 M
|
| Income Before Tax |
$184.95 M
|
$56.33 M
|
-$194.23 M
|
$155.18 M
|
$241.20 M
|
-$145.29 M
|
$69.20 M
|
$121.28 M
|
-$56.02 M
|
$96.17 M
|
| Income Before Tax Ratio |
17.17
|
5.47
|
-23.48
|
23.95
|
27
|
-19.12
|
10.2
|
21.58
|
-11.67
|
22.2
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
$184.95 M
|
$56.33 M
|
-$194.23 M
|
$155.18 M
|
$241.20 M
|
-$145.29 M
|
$69.20 M
|
$121.28 M
|
-$56.02 M
|
$96.17 M
|
| Net Income Ratio |
17.17
|
5.47
|
-23.48
|
23.95
|
27
|
-19.12
|
10.2
|
21.58
|
-11.67
|
22.2
|
| EPS |
3.55 |
1.14 |
-4.1 |
3.42 |
5.5 |
-3.39 |
1.64 |
2.98 |
-1.44 |
2.58 |
| EPS Diluted |
3.55 |
1.14 |
-4.1 |
3.42 |
5.5 |
-3.39 |
1.64 |
2.98 |
-1.44 |
2.58 |
| Weighted Average Shares Out |
$52.13 M
|
$49.44 M
|
$47.34 M
|
$45.43 M
|
$43.87 M
|
$42.83 M
|
$42.22 M
|
$40.65 M
|
$39.00 M
|
$37.30 M
|
| Weighted Average Shares Out Diluted |
$52.13 M
|
$49.44 M
|
$47.34 M
|
$45.43 M
|
$43.87 M
|
$42.83 M
|
$42.22 M
|
$40.65 M
|
$39.00 M
|
$37.30 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
